Loading...
XKRX
207940
Market cap51bUSD
Oct 30, Last price  
1,487,000.00KRW
1D
8.86%
1Q
0.13%
Jan 2017
540.48%
IPO
498.84%
Name

Samsung Biologics Co Ltd

Chart & performance

D1W1MN
XKRX:207940 chart
P/E
38.58
P/S
15.11
EPS
38,546.46
Vol. 1Y
44.98%
Shs. 5Y
1.23%
Rev. 5Y
31.37%
Div Yld LY
—
Div Yld TTM
—
Revenues
4.56t
+30.31%
105,148,784,00091,278,029,000294,622,021,000464,629,334,000535,805,801,000701,591,860,0001,164,776,874,0001,568,006,928,0003,001,295,198,0003,694,588,767,0003,497,145,676,0004,556,971,695,000
Net income
1.78t
+64.71%
-95,909,288,0001,920,178,774,000-176,823,410,000-96,972,116,000224,109,195,000202,904,099,000240,974,800,000393,589,468,000798,056,210,000857,691,298,0001,083,315,886,0001,784,352,061,000
CFO
2.25t
+35.47%
-108,299,232,940-265,513,751,570-62,661,298,030149,816,327,600-32,417,327,33010,153,615,000202,090,027,000454,596,217,000953,047,810,0001,666,228,521,0001,659,255,403,0002,247,807,427,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.

Key people

Diane Black
Vice President · since 2025
Pierre Catignol
Vice President · since 2021
James Choi
Vice President · since 2021
Gyu Ho Lee
Vice President · since 2024
Ho Seong Min
Vice President · since 2023
Kevin Sharp
Vice President · since 2024
Javier Camposano
Assistant Managing Director · since 2024
Seong Hwan Cho
Assistant Managing Director · since 2023
Yeong Jin Cho
Assistant Managing Director · since 2021
Seong Yil Cho
Assistant Managing Director · since 2022
Yeong Han Gu
Assistant Managing Director · since 2022
Yeon Jin Hong
Assistant Managing Director · since 2023
Do Yeong Huh
Assistant Managing Director · since 2021
Yin Chan Hwang
Assistant Managing Director · since 2024
Yong Hwan Jin
Assistant Managing Director · since 2020
Hyeong Nam Jung
Assistant Managing Director · since 2024
Ja Hun Kang
Assistant Managing Director · since 2021
Jin Han Kim
Assistant Managing Director · since 2025
Hui Jeong Kim
Assistant Managing Director · since 2021
Christina Kim
Assistant Managing Director · since 2023
IPO date
Nov 10, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT